Does Retatrutide Cause Acid Reflux?

Retatrutide, an investigational triple hormone receptor agonist developed by Eli Lilly, has no UK marketing authorisation and is accessible only within authorised clinical trials. Whether retatrutide causes acid reflux is a clinically relevant question, as gastrointestinal symptoms were among the most commonly reported adverse events in published trial data. This article summarises what clinical trial evidence currently shows about reflux and digestive side effects, who may be more susceptible, and when to seek medical advice. It is intended to inform, not to promote a medicine that has not been evaluated by the MHRA for routine clinical use.

What Is Retatrutide and Where Does It Stand with UK Regulators?

Retatrutide has no UK marketing authorisation and cannot be prescribed outside an authorised clinical trial. The MHRA has not evaluated it for routine use, and NICE has issued no guidance on it.

Retatrutide does not hold a marketing authorisation in the UK or anywhere else, and it can only be accessed within an authorised clinical trial.^[9] It is an investigational medicine developed by Eli Lilly that acts on three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[2][3] This triple agonist mechanism distinguishes it pharmacologically from currently licensed treatments. No published head-to-head comparisons between retatrutide and authorised medicines have been identified in the peer-reviewed literature at the time of writing; if such data emerge from the ongoing trial programme, this position should be reviewed.

Because retatrutide has no UK marketing authorisation, the MHRA has not evaluated it for routine clinical use, and NICE has issued no guidance on it. It cannot be prescribed or supplied outside an authorised clinical trial. Anyone who encounters retatrutide being sold online should be aware that such a product would not be a licensed medicine and could be falsified or unsafe.

For people interested in weight management or metabolic health, licensed treatments do exist and can be discussed with a GP. The clinical research programme for retatrutide includes the TRIUMPH and TRANSCEND trial series.^[4] Phase 3 results from some of these trials have been reported at congresses and in peer-reviewed publications, and the evidence base continues to develop. No UK authorisation date has been announced.

Which gut-related side effects have clinical trials reported?

The 2023 Phase 2 trial found nausea, vomiting, diarrhoea, and constipation were more common with retatrutide than placebo, with reflux-type symptoms consistent with GLP-1-mediated slowing of gastric emptying.

Clinical trial data for retatrutide indicate that gastrointestinal side effects, including symptoms consistent with acid reflux, nausea, and vomiting, were among the most commonly reported adverse events. Published findings from the Phase 2 trial reported in the New England Journal of Medicine (2023), involving adults with obesity over 48 weeks, found that nausea, diarrhoea, vomiting, and constipation occurred more frequently in participants receiving retatrutide than in those receiving placebo, and that these effects were generally dose-dependent.^[2][3] Phase 3 data from the TRANSCEND and TRIUMPH programmes have since been reported at major congresses and in peer-reviewed publications; these larger datasets are expected to provide a more detailed characterisation of gastrointestinal tolerability, including rates of discontinuation due to gastrointestinal adverse events, though the full peer-reviewed record is still emerging.

Symptoms resembling acid reflux, such as heartburn, regurgitation, and upper abdominal discomfort, are consistent with the known pharmacology of GLP-1 receptor agonism. GLP-1 receptor activation slows gastric emptying, which can increase gastric pressure and the likelihood of reflux-type symptoms.^[7][8] The additional glucagon receptor activity in retatrutide may further influence gastrointestinal motility; this is a theoretical inference based on receptor pharmacology rather than a finding directly demonstrated in published retatrutide-specific data.

Because retatrutide is not authorised, no UK Summary of Product Characteristics exists. Safety data therefore come from trial reports rather than a regulatory summary. Suspected adverse events in trial participants should be reported to the trial team under the study protocol; they can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Who seems most likely to experience digestive symptoms?

Higher doses and dose escalation are associated with greater gastrointestinal symptoms, and people with pre-existing GORD or gastroparesis may be at increased risk of worsening reflux-type effects.

Participants in retatrutide trials who received higher doses appeared more likely to report gastrointestinal symptoms, suggesting a dose-response relationship for these effects.^[2][3] This pattern is consistent with what has been observed with other GLP-1 receptor agonist medicines, where the incidence and severity of nausea, vomiting, and reflux-type symptoms tend to be higher at the start of treatment and during dose escalation, then diminish over time as the body adapts.^[8]

People with a pre-existing history of gastro-oesophageal reflux disease (GORD), gastroparesis, or other upper gastrointestinal conditions may be at greater risk of experiencing or noticing worsening of reflux-type symptoms when gastric emptying is further slowed by a GLP-1 receptor agonist mechanism.^[8] Trial protocols for investigational medicines typically exclude participants with certain gastrointestinal conditions; the specific exclusion criteria for individual TRIUMPH and TRANSCEND trials are set out in the respective ClinicalTrials.gov entries and protocol appendices. This means published safety data may not fully reflect the experience of people with these comorbidities.

Other factors that commonly influence reflux symptoms, such as body weight, dietary habits, alcohol intake, smoking, and concurrent use of medicines including non-steroidal anti-inflammatory drugs (NSAIDs), are relevant regardless of the medicine being studied. Because retatrutide is available only within authorised clinical trials, trial teams assess eligibility carefully and monitor participants throughout. Outside of a trial setting, there is no basis on which to predict an individual's likelihood of experiencing these symptoms.

When should you speak to a doctor about stomach or reflux symptoms?

Trial participants should report symptoms promptly to their trial team; anyone outside a trial with persistent reflux should contact their GP, and severe upper abdominal pain requires urgent attention via 999 or A&E.

Anyone participating in a retatrutide clinical trial who develops new or worsening stomach or reflux symptoms should report these promptly to their trial team, as this is the appropriate and required route for safety monitoring within a study protocol. Trial participants should also carry their study ID card and inform any emergency clinician that they are enrolled in a clinical trial, so that the treating team can contact the study team if needed. Trial participants are not managing these medicines independently, and the trial team is best placed to assess whether symptoms are related to the investigational medicine and whether any adjustment is needed.

For people not in a trial who are experiencing persistent acid reflux, heartburn, or upper abdominal discomfort, the right step is to contact their GP. A GP can assess whether symptoms have an identifiable cause, review any current medicines that might contribute, and refer for further investigation if needed. NICE guidance on dyspepsia and GORD (CG184) identifies the following as features that should prompt urgent review: difficulty swallowing (dysphagia) at any age; gastrointestinal bleeding; iron-deficiency anaemia; unintentional weight loss, particularly with upper abdominal pain in people aged 55 or over; and persistent vomiting with weight loss. These features warrant prompt assessment and should not be attributed to a medicine without clinical evaluation.

If symptoms are severe, such as intense upper abdominal pain that radiates to the back, which can be a feature of acute pancreatitis, this warrants urgent medical attention via 999 or attendance at an accident and emergency department.^[6] Pancreatitis has been reported in association with GLP-1 receptor agonist medicines as a class, including post-marketing reports of necrotising pancreatitis.^[1] For urgent but non-emergency concerns outside of GP hours, NHS 111 can provide advice. People should never attempt to obtain retatrutide outside of an authorised clinical trial, as any product sold through other channels would not be a licensed medicine.

Frequently Asked Questions